Established last year, the $15-20 million Consortium Bereshit for Cell Therapy is composed of Israel’s – and some of the world’s – leading stem cell researchers.Israeli scientists are pushing the boundaries of an already cutting-edge field: stem cell research. They …
Coming together from both academia and industry, they have joined to form a consortium aimed to further develop stem cell-based therapies. The Consortium Bereshit for Cell Therapy testifies to the importance of stem cell research in Israel.
Established last year, this $15-20 million project of the Chief Scientist’s Office of the Ministry of Industry and Trade is composed of Israel’s – and some of the world’s – leading stem cell researchers.
“Our main goal is to create embryonic stem cells that will be FDA approved,” the group’s technical manager, Iris Lewin, told ISRAEL21c. “We are also working to characterize the cells: to understand if they will become cells of the heart, pancreas, liver, etc. At the same time, we must characterize the cells’ genome, learn to isolate them and influence them to develop into specific organs.”
Another major focus of the Consortium is ‘tool development’. Attempting to bring cell therapy products into clinical uses, researchers here attack problems of cell availability and viability, cryopreservation and safe and efficient ways to transfer cells from lab to operating room.
“Medicines only treat symptoms, not diseases themselves,” says Dr. Arik Hasson, the head of the Stem Cell Consortium Project and CEO of Gamida-Cell. “Stem cell therapy can offer a real solution to nervous system disease and cancer. It can be applied to cardiac disorders, renal failure, diabetes mellitus, autoimmune disease, bone and joint disorders, genetic illness and skin wounds,” he told ISRAEL21c.
Hasson points out that while organ transplants have helped victims of liver, heart and kidney disease, they are accompanied by numerous problems. As the demand is far greater than the supply, not enough organs are available for patients in need. In addition, after transplants, the body often recognizes new organs as foreign objects, and destroys them. To counter this, patients receive immuno-suppressive medication, rendering their bodies susceptible to bacteria, viruses and cancer.
“Stem cells provide an ideal solution for the problems associated with transplantation,” says Hasson. “They will allow for organ regeneration.”
There are two major types of stem cells, embryonic and adult, explains Hasson. Embryonic cells come from the ‘surplus’ embryos of IVF treatments. They are taken some 72 hours after the creation of a zygote, and are pluripotent. That is, they have the ability to become all body cells except for those forming the placenta or amniotic sac. Currently, these cells spontaneously develop into specific organs. Hasson estimates that within a decade, scientists will be able to determine which organs the cells will form.
Adult stem cells, found in the bone marrow, umbilical cord blood and peripheral blood, are not associated with ethical issues. Allowing for the regeneration of systems including blood vessels, fat tissue, cartilage, bone and muscle, these cells, says Hasson “have enormous potential for different therapies.”
Already, for decades, they have been used in skin grafts, and in treating leukemia and lymphoma patients.
Holding that both types of stem cells have drawbacks and advantages, Israel’s Consortium Bereshit is committed to their mutual development. The activity of member companies runs the gamut of cell stem research:
** Gamida-Cell works to expand, outside the body, the number of hematopoietic (blood and lymph) stem cells for treatment of cancer and autoimmune diseases, as well as for use in future regenerative cell-based medicines, including heart and pancreatic tissue repair.
** Proneuron Biotechnologies aims to develop and commercialize therapies for different central nervous system (CNS) disorders. Proneuron is currently focusing on a treatment for spinal cord injuries and other neurological disorders, which until now were considered incurable.
** Prochon Biotech Ltd. specializes in ex-vivo expansion of cells for use in treating bone and cartilage disorders. Currently focused on finding a cure for Achondroplasia, the most common form of short-limbed dwarfism, the company develops biology-based products for tissue regeneration and growth.
** M.G.V. Systems develops novel therapeutic modalities for cardiovascular medicine based on gene and cell therapy. Using those cells that produce blood vessels and genetically manipulating them, the company is developing vascular grafts that will prevent graft failure, as well as modified cells that will promote the production of new blood vessels that will bypass occluded arteries.
** QUANTOMIX is commercializing its breakthrough technology, which enables direct imaging of fully hydrated samples in an electron microscope. Its products allow for the examination of cells and tissues without conventional treatments such as drying, deep freezing and sectioning. This should pave the way to improved understanding of biomedical processes, patient care and more effective pharmaceutical research.
Other related companies, while not Consortium members, are also involved in ground-breaking stem cell work. For example, BrainStorm Cell Therapeutics develops solutions for terminal neurodegenerative diseases such as Parkinson’s Disease, Multiple Sclerosis and Amyotrophic Lateral Sclerosis (ALS).
Pluristem Life Systems Inc. expands the numbers of hematopoietic cells, thus enabling treatment of adult patients who require bone marrow transplants, but are unable to find compatible donors. To counter the problems involved in organ transplants, Tissera Inc. is working on tissue transplantation therapies based on an approach employing organ-specific precursor tissues.
How has Israel, a country the size of the smallest US states, risen to such a position of prominence in this crucial field?
First of all, according to Hasson, Israel is disproportionately represented in all the natural sciences. In many US universities, he says, the number of Israeli graduate students in biology-related fields approaches that of their colleagues from India and China, countries that have populations more than 200 times greater than Israel’s. In addition, he says, Israelis are forward-thinking, and are attracted to the ‘hottest’ fields of science.
Perhaps most significant is the fact that ethical issues, which have curbed stem cell research in the US and elsewhere, are muted in Israel. There is no law regulating stem cell research in Israel, and use of embryos for such research is allowed. In the US, embryonic stem cell research is a burning issue that played a major role in the recent presidential election. As of 2001, US President George W. Bush prohibited the federal financing of embryonic stem cell research, although the authorization of such projects is left to the discretion of each state.
These radically different approaches can be partially linked to different religious beliefs.
In the view of Roman and Orthodox Catholics and many other Christians, human beings come into existence with the fertilization of the ovum by the sperm. Thus, as the earliest embryos are human, ending their lives is unthinkable – even for therapeutic applications. IVF procedures, which routinely result in ‘surplus’ embryos that will never develop, are unacceptable. This prohibits the very source of embryos for stem cell research.
Jewish Biblical and Talmudic Law holds that the embryo acquires full human status only at birth. In connection to the pre-implantation embryo, Jewish Law dictates that genetic materials outside the uterus have no legal status since they are not part of a human being until implanted in the womb. Even in the uterus, the embryo is considered a ‘formed’ human fetus only after the first 40 days. And as the commandment to save lives is central to Judaism, the creation of embryos by cloning for therapeutic purposes is justifiable.